HUTCHMED (China) (HCM) Cash from Financing Activities (2018 - 2021)
HUTCHMED (China)'s (HCM) quarterly Cash from Financing Activities came in at $605.1 million in Q2 2021, up 4315.1% year-on-year from $13.7 million in Q2 2020, and up 2362.23% on a QoQ basis from -$26.7 million in Q1 2021.
HUTCHMED (China) (HCM) Cash from Financing Activities (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HCM) has 4 years of Cash from Financing Activities data on file, last reported at $605.1 million in Q2 2021.
- On a quarterly basis, Cash from Financing Activities rose 4315.1% year-over-year to $605.1 million in Q2 2021; TTM through Jun 2021 was $674.7 million, a 442.5% increase from a year earlier, with the FY2025 full-year figure at $7.8 million, up 125.55% from the prior year.
- Cash from Financing Activities for Q2 2021 stood at $605.1 million, up from -$26.7 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for HCM reached as high as $605.1 million in Q2 2021 and fell as low as -$29.2 million in Q2 2019.
- Historically, Cash from Financing Activities has averaged $56.8 million across 4 years, with a median of -$161000.0 in 2018.
- Across the five-year window, Cash from Financing Activities plunged 1017.16% in 2019 and surged 32093.64% in 2020, its largest moves.
- Year by year, Cash from Financing Activities stood at $16.0 million in 2018, then soared by 67.63% to $26.9 million in 2019, then tumbled by 153.36% to -$14.4 million in 2020, then soared by 4315.1% to $605.1 million in 2021.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $605.1 million in Q2 2021, -$26.7 million in Q1 2021, and -$14.4 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | HUTCHMED (China) | 241.90 Mn | 243.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 605.08 Mn |
| Jun 30, 2021 | 605.08 Mn |
| Mar 31, 2021 | -26.75 Mn |
| Mar 31, 2021 | -26.75 Mn |
| Jun 30, 2020 | -14.36 Mn |
| Jun 30, 2020 | -14.36 Mn |
| Mar 31, 2020 | 110.70 Mn |
| Mar 31, 2020 | 110.70 Mn |
| Dec 31, 2019 | 26.90 Mn |
| Dec 31, 2019 | 26.90 Mn |
| Sep 30, 2019 | 1.12 Mn |
| Sep 30, 2019 | 1.12 Mn |
| Jun 30, 2019 | -29.17 Mn |
| Jun 30, 2019 | -29.17 Mn |
| Mar 31, 2019 | -346,000.00 |
| Mar 31, 2019 | -346,000.00 |
| Dec 31, 2018 | 16.05 Mn |
| Dec 31, 2018 | 16.05 Mn |
| Sep 30, 2018 | 24,000.00 |
| Sep 30, 2018 | 24,000.00 |